Yorktown Management & Research Co Inc acquired a new stake in Afya Limited (NASDAQ:AFYA - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,900 shares of the company's stock, valued at approximately $321,000.
A number of other institutional investors have also modified their holdings of the company. Public Employees Retirement System of Ohio increased its position in shares of Afya by 40.0% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,800 shares of the company's stock worth $44,000 after acquiring an additional 800 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Afya by 1,099.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,031 shares of the company's stock worth $64,000 after acquiring an additional 3,695 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Afya by 2,115.9% in the 4th quarter. JPMorgan Chase & Co. now owns 6,670 shares of the company's stock valued at $106,000 after acquiring an additional 6,369 shares during the last quarter. Aquatic Capital Management LLC lifted its stake in Afya by 47.6% during the fourth quarter. Aquatic Capital Management LLC now owns 9,300 shares of the company's stock worth $148,000 after purchasing an additional 3,000 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in Afya by 41.9% in the fourth quarter. Van ECK Associates Corp now owns 9,677 shares of the company's stock worth $154,000 after purchasing an additional 2,856 shares during the period. Hedge funds and other institutional investors own 88.02% of the company's stock.
Afya Stock Performance
AFYA traded up $0.18 during trading hours on Tuesday, hitting $17.66. The company's stock had a trading volume of 50,191 shares, compared to its average volume of 123,785. The firm has a market capitalization of $1.66 billion, a PE ratio of 13.38, a PEG ratio of 0.59 and a beta of 0.60. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.41. Afya Limited has a fifty-two week low of $14.52 and a fifty-two week high of $19.90. The company has a 50-day simple moving average of $18.50 and a 200 day simple moving average of $17.24.
Analysts Set New Price Targets
AFYA has been the subject of a number of research reports. Morgan Stanley downgraded Afya from an "equal weight" rating to an "underweight" rating and decreased their target price for the company from $19.00 to $17.00 in a research note on Tuesday, March 11th. UBS Group restated a "neutral" rating and set a $19.50 price objective (up from $17.50) on shares of Afya in a research note on Thursday, June 12th. Finally, Wall Street Zen upgraded Afya from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Afya presently has an average rating of "Hold" and a consensus target price of $17.60.
Read Our Latest Analysis on Afya
About Afya
(
Free Report)
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
Featured Stories

Before you consider Afya, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Afya wasn't on the list.
While Afya currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.